Intravenous Pharmacokinetics And Security Of Long-acting Erythropoiesis Stimulating Protein In Dialysis Patients

43 patients (0.225, 0.45, 0.9, 1.8, 3.6ug/Kg groups) who were stableon hemodialysis over 3 months were included to evaluate thepharmacokinetics and security of darbepoetin alfa. Blood samples weretaken before and after dosing to measure the serum levels of darbepoetinalfa using the Quantikine IVD human erythropoietin enzyme-linkedimmunosorbent assay. Pharmacokinetic parameters such as AUC, CL, Vd,t1/2 were estimated. And the vital signs, clinical symptoms and laboratoryexaminations before and after dosing were monitored to evaluated thesecurity of darbepoetin alfa. The area under the serum concentration-timecurve (AUC) was positive related to dose and serum concentrationsdeclined in a biphasic manner. The mainly relational side effect washypertension aggravation.In general, darbepoetin alfa represents a new generation of long-actingerythropoietic proteins. Darbepoetin alfa is well tolerated and has a safetyprofile. The most common adverse event is hypertension.